Coalition for Reducing Bureaucracy in Clinical Trials 2025 Recommendations
All medicines need to pass rigorous tests before they can [...]
Kidney cancer cases are projected to double by 2050
Lifestyle risk factors such as obesity, smoking, lack of exercise, [...]
Cancer waiting times: Latest updates
Recent years have seen pressure on NHS cancer services increase, [...]
First NICE guideline on kidney cancer
A new draft guideline, issued by the National Institute for [...]
KIM-1 as a potential biomarker for kidney cancer
Currently, the search for a reliable test to identify patients [...]
Stoptober is back!
Because smoking is one of the main risk factors for [...]
Audit of NHS shows only 1% of kidney cancer patients are enrolled in clinical trials
We are pleased to announce the publication of the second [...]
Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
First-line benmelstobart plus anlotinib versus sunitinib in advanced kidney cancer
A new immunotherapy called benmelstobart, which blocks the action of [...]
New immunotherapy for metastatic kidney cancer could help improve outcomes
Researchers from the University of California in Los Angeles (UCLA) [...]
